Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: Immortal time bias in observational studies

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 1, 2003, Pages 49-53

  Suissa, Samy ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cohort studies; Databases; Epidemiologic biases; Epidemiologic methods; Treatment effectiveness

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; KETOTIFEN; NEDOCROMIL; THEOPHYLLINE; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; STEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TIME; CANADA; DRUG COMBINATION; EPIDEMIOLOGY; FOLLOW UP; HOSPITAL READMISSION; INHALATIONAL DRUG ADMINISTRATION; OBSERVATION; PROPORTIONAL HAZARDS MODEL; STANDARD; STATISTICS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; ANTI-INFLAMMATORY AGENTS; BIAS (EPIDEMIOLOGY); DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MORBIDITY; OBSERVATION; PATIENT READMISSION; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESEARCH DESIGN; SASKATCHEWAN; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0041865230     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200210-1231OC     Document Type: Article

References (21)

1. Anonymous. National Hospital Discharge Survey: 1980-1998. Washington, DC: National Center for Health Statistics; 2000.
2. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000;117:1S-4S.
3. Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:341-342.
4. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-344.
5. van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, Similowski T, Akkermans RP, Pasker-de Jong PC, Dekhuijzen PN, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14.
6. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998;351:773-780.
7. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998;53:477-482.
8. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-1823.
9. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-1953.
10. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
11. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
12. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
13. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-584.
14. Sin DD, Man SFP. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003;21:1-7.
15. Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting β-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74.
16. Walker AM. Observation and inference: an introduction to the methods of epidemiology. Newton Lower Falls, MA: Epidemiology Resources Inc.; 1991.
17. Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Hagerstown, MD: Lippincott-Raven; 1998.
18. Downey W, Beck P, McNutt M, Stang M, Osei W, Nichol J. Health databases in Saskatchewan. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. New York: John Wiley and Sons, Ltd.; 2000. p. 325-346.
19. Vestbo J. Another piece of the inhaled corticosteroids-in-COPD puzzle. Am J Respir Crit Care Med 2001;164:514-515.
20. Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000;55:194-197.
21. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001;17:380-385.